Cargando…

Effect of AZD0530 on Cerebral Metabolic Decline in Alzheimer Disease: A Randomized Clinical Trial

IMPORTANCE: Oligomeric amyloid-β peptide binds to cellular prion protein on the neuronal cell surface, activating intracellular fyn kinase to mediate synaptotoxicity and tauopathy. AZD0530 is an investigational kinase inhibitor specific for the Src family, including fyn, that has been repurposed for...

Descripción completa

Detalles Bibliográficos
Autores principales:	van Dyck, Christopher H., Nygaard, Haakon B., Chen, Kewei, Donohue, Michael C., Raman, Rema, Rissman, Robert A., Brewer, James B., Koeppe, Robert A., Chow, Tiffany W., Rafii, Michael S., Gessert, Devon, Choi, Jiyoon, Turner, R. Scott, Kaye, Jeffrey A., Gale, Seth A., Reiman, Eric M., Aisen, Paul S., Strittmatter, Stephen M.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	American Medical Association 2019
Materias:	Original Investigation
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6646979/ https://www.ncbi.nlm.nih.gov/pubmed/31329216 http://dx.doi.org/10.1001/jamaneurol.2019.2050

Ejemplares similares

A phase Ib multiple ascending dose study of the safety, tolerability, and central nervous system availability of AZD0530 (saracatinib) in Alzheimer’s disease
por: Nygaard, Haakon B, et al.
Publicado: (2015)

Activation of MAPK signalling results in resistance to saracatinib (AZD0530) in ovarian cancer
por: McGivern, Niamh, et al.
Publicado: (2017)

Phase I study of saracatinib (AZD0530) in combination with paclitaxel and/or carboplatin in patients with solid tumours
por: Kaye, S, et al.
Publicado: (2012)

The effect of the dual Src/Abl kinase inhibitor AZD0530 on Philadelphia positive leukaemia cell lines
por: Gwanmesia, Patricia Mambou, et al.
Publicado: (2009)

AZD0530 sensitizes drug‐resistant ALK‐positive lung cancer cells by inhibiting SRC signaling
por: Zhao, Yi, et al.
Publicado: (2017)

The down syndrome biomarker initiative (DSBI) pilot: proof of concept for deep phenotyping of Alzheimer’s disease biomarkers in down syndrome
por: Rafii, Michael S., et al.
Publicado: (2015)

Feasibility study for detection of retinal amyloid in clinical trials: The Anti‐Amyloid Treatment in Asymptomatic Alzheimer's Disease (A4) trial
por: Ngolab, Jennifer, et al.
Publicado: (2021)

Synergistic effect of STAT3-targeted small interfering RNA and AZD0530 against glioblastoma in vitro and in vivo
por: Liu, Qingjun, et al.
Publicado: (2019)

Exploring the benefits of in-diet versus repeated oral dosing of saracatinib (AZD0530) in chronic studies: insights into pharmacokinetics and animal welfare
por: Vasanthi, Suraj S., et al.
Publicado: (2023)

Aromatase inhibition plus/minus Src inhibitor saracatinib (AZD0530) in advanced breast cancer therapy (ARISTACAT): a randomised phase II study
por: Oswald, Ailsa J., et al.
Publicado: (2023)

Fyn kinase inhibition as a novel therapy for Alzheimer’s disease
por: Nygaard, Haakon B, et al.
Publicado: (2014)

A randomized, double-blind, placebo-controlled trial of resveratrol for Alzheimer disease
por: Turner, R. Scott, et al.
Publicado: (2015)

Intranasal insulin modulates cerebrospinal fluid markers of neuroinflammation in mild cognitive impairment and Alzheimer’s disease: a randomized trial
por: Kellar, Derek, et al.
Publicado: (2022)

An EMT spectrum defines an anoikis-resistant and spheroidogenic intermediate mesenchymal state that is sensitive to e-cadherin restoration by a src-kinase inhibitor, saracatinib (AZD0530)
por: Huang, R Y-J, et al.
Publicado: (2013)

Results of a Randomized, Double-Blinded, Placebo-Controlled, Phase 2.5 Study of Saracatinib (AZD0530), in Patients with Recurrent Osteosarcoma Localized to the Lung
por: Baird, Kristin, et al.
Publicado: (2020)

Mechanisms of disease-modifying effect of saracatinib (AZD0530), a Src/Fyn tyrosine kinase inhibitor, in the rat kainate model of temporal lobe epilepsy
por: Sharma, Shaunik, et al.
Publicado: (2021)

The AHEAD 3–45 Study: Design of a prevention trial for Alzheimer’s disease
por: Rafii, Michael S., et al.
Publicado: (2023)

Early-stage Alzheimer disease: getting trial-ready
por: Aisen, Paul S., et al.
Publicado: (2022)

Demonstration of safety of intravenous immunoglobulin in geriatric patients in a long-term, placebo-controlled study of Alzheimer's disease
por: Gelmont, David, et al.
Publicado: (2016)

Applications of Neuroimaging to Disease-Modification Trials in Alzheimer’s Disease
por: Fleisher, Adam S., et al.
Publicado: (2009)

Safety and tolerability of lumbar puncture for the evaluation of Alzheimer's disease
por: Baldaranov, Dobri, et al.
Publicado: (2023)

The Trial-Ready Cohort for Preclinical/Prodromal Alzheimer’s Disease (TRC-PAD) Project: An Overview
por: Aisen, P.S., et al.
Publicado: (2020)

Cross-validation of optimized composites for preclinical Alzheimer's disease
por: Donohue, Michael C., et al.
Publicado: (2016)

Bayesian latent time joint mixed-effects model of progression in the Alzheimer's Disease Neuroimaging Initiative
por: Li, Dan, et al.
Publicado: (2018)

Predicting the course of Alzheimer’s progression
por: Iddi, Samuel, et al.
Publicado: (2019)

Cellular Prion Protein Mediates Impairment of Synaptic Plasticity by Amyloid-β Oligomers
por: Laurén, Juha, et al.
Publicado: (2009)

Recent developments in Alzheimer's disease therapeutics
por: Rafii, Michael S, et al.
Publicado: (2009)

Advances in Alzheimer’s Disease Drug Development
por: Rafii, Michael S, et al.
Publicado: (2015)

Intranasal Insulin Reduces White Matter Hyperintensity Progression in Association with Improvements in Cognition and CSF Biomarker Profiles in Mild Cognitive Impairment and Alzheimer’s Disease
por: Kellar, D., et al.
Publicado: (2021)

P05.30. Integrating complementary and alternative medicine into mainstream health care: an empirical study of seven health care services in Australia
por: Singer, J, et al.
Publicado: (2012)

TRC-PAD: Accelerating Recruitment of AD Clinical Trials through Innovative Information Technology
por: Jimenez-Maggiora, G.A., et al.
Publicado: (2020)

Resveratrol regulates neuro-inflammation and induces adaptive immunity in Alzheimer’s disease
por: Moussa, Charbel, et al.
Publicado: (2017)

The potential health impact of restricting less-healthy food and beverage advertising on UK television between 05.30 and 21.00 hours: A modelling study
por: Mytton, Oliver T., et al.
Publicado: (2020)

Combination of AZD3463 and DZNep Prevents Bone Metastasis of Breast Cancer by Suppressing Akt Signaling
por: He, Wenxin, et al.
Publicado: (2021)

Disparities by Race and Ethnicity Among Adults Recruited for a Preclinical Alzheimer Disease Trial
por: Raman, Rema, et al.
Publicado: (2021)

Brivaracetam, but not ethosuximide, reverses memory impairments in an Alzheimer’s disease mouse model
por: Nygaard, Haakon B, et al.
Publicado: (2015)

Safety, tolerability, pharmacokinetics and pharmacodynamics of AZD8055 in advanced solid tumours and lymphoma
por: Naing, A, et al.
Publicado: (2012)

Predicting amyloid risk by machine learning algorithms based on the A4 screen data: Application to the Japanese Trial‐Ready Cohort study
por: Sato, Kenichiro, et al.
Publicado: (2021)

Alzheimer Amyloid-β Oligomer Bound to Post-Synaptic Prion Protein Activates Fyn to Impair Neurons
por: Um, Ji Won, et al.
Publicado: (2012)

Functional Brain Imaging in the Clinical Assessment of Consciousness
por: Rafii, Michael S., et al.
Publicado: (2010)

Cannot write session to /tmp/vufind_sessions/sess_080e437nnr06nt6ifd146uv3db